MerTK-dependent efferocytosis by monocytic-MDSCs mediates resolution of post-lung transplant injury

Abstract

Insights

Monocytic myeloid-derived suppressor cells (M-MDSCs) utilize MerTK-dependent efferocytosis to resolve lung ischemia-reperfusion injury (IRI) after lung transplantation (LTx). This mechanism is crucial for mitigating IRI and improving outcomes in LTx recipients.

Area of Science:

  • Immunology
  • Transplantation Biology
  • Cellular Biology

Background:

  • Lung transplantation (LTx) is essential for end-stage lung disease but is often complicated by ischemia-reperfusion injury (IRI).
  • Chronic lung allograft dysfunction (CLAD) remains a significant challenge, necessitating strategies to mitigate IRI and improve long-term graft survival.
  • The precise mechanisms underlying IRI resolution and their therapeutic potential are not fully understood.

Approach:

  • Investigated the role of MerTK (receptor Mer tyrosine kinase) on monocytic myeloid-derived suppressor cells (M-MDSCs) in efferocytosis following lung IRI.
  • Utilized single-cell RNA sequencing of post-LTx patient samples and murine LTx models.
  • Assessed lung function, IRI markers, and efferocytosis in wild-type, MDSC-deficient, and MerTK-deficient mice.

Key Points:

  • Downregulation of MerTK-related efferocytosis genes observed in M-MDSCs of CLAD patients.
  • MerTK expression and efferocytosis by M-MDSCs increased during IRI resolution in wild-type mice, but not in deficient models.
  • Adoptive transfer of M-MDSCs ameliorated lung dysfunction and inflammation in murine IRI models.
  • In vitro studies confirmed MerTK-dependent efferocytosis of apoptotic neutrophils by M-MDSCs.

Conclusions:

  • MerTK-dependent efferocytosis by M-MDSCs plays a critical role in resolving lung IRI post-LTx.
  • This pathway represents a potential therapeutic target for improving LTx outcomes.
  • Understanding M-MDSC function in efferocytosis is key to managing IRI complications.